Skip to main content

Branded

  • Sanofi Pasteur to start shipping new flu vaccines

    SWIFTWATER, Pa. – Sanofi Pasteur on Tuesday announced today that its first doses of Fluzone  for the 2016-2017 influenza season have been released by the U.S. Food and Drug Administration for shipment.
    In the 2015-2016 influenza season, 50% of seniors who were vaccinated received Fluzone High-Dose vaccine, and this number is expected to rise to 60% in the coming season.

  • Octreotide Acetate Injection now available from Teva

    NORTH WALES, Pa. -- Teva announced that its Octreotide Acetate Injection, 50 mcg/mL, is back in stock and ready to order.

    The product is AP rated to Sandostatin (octreotide acetate) Injection. Teva now offers Octreotide Acetate Injection in 50 mcg/mL,100 mcg/mL, 200 mcg/mL, 500 mcg/mL, and 1000 mcg/mL.

     

     

  • NCPA forms Innovation Center to drive healthcare evolution through independent pharmacy

    ALEXANDRIA, Va. - The National Community Pharmacists Association on Tuesday announced the establishment of a new Innovation Center that is intended to further assist and speed up the evolution of independent community pharmacies in a changing health care environment.

  • NACDS joins 37 Congress leaders in supporting TRICARE cost-saving dispensing pilot

    ARLINGTON, Va. – The National Association of Chain Drug Stores on Wednesday publicly thanked the 37 members of the U.S. House of Representatives who have sent a letter to House and Senate negotiators, urging them to advance a TRICARE pilot program as part of the FY2017 National Defense Authorization Act.

  • Namzaric gets FDA approval for expanded label

    SILVER SPRING, Md. — Allergan and Adamas Pharmaceuticals on Tuesday announced an expanded label for their Namzaric (memantine and donepezil hydrochlorides). It can now be used by patients with moderate to severe Alzheimer’s disease. 
     
    Patients currently stabilized on Aricept (donepezil HCL, 10 mg) can begin combination therapy with Namzaric. 
     

  • Lilly, Boehringer Ingelheim get expanded Synjardy indication

    SILVER SPRING, Md. — Eli Lilly & Co. and Boehringer Ingelheim announced Tuesday that the Food and Drug Administration had approved an expanded indication for their Synjardy (empagliflozin and metformin hydrochloride) tablets. 
     
    The new indication makes the drug available for treatment-naïve adults with type 2 diabetes as an adjunct to diet and exercise as a way of improving glycemic control. 
     

  • FDA approves Belviq XR from Eisai, Arena

    SILVER SPRING, Md. — The Food and Drug Administration has approved Eisai’s and Arena Pharmaceuticals’ Belviq XR (lorcaserin HCl) extended-release 20-mg tablets, the companies announced Tuesday. 
     
    The drug is a new formulation of lorcaserin that can offer patients once-daily dosing and could help maintain weight loss, as it’s indicated for use in patients for chronic weight management. Following the approval, Arena will receive a $10 million milestone payment. 
     

  • Cefaly Technology relaunches Rx-only migraine wearable

    NEW YORK - Cefaly Technology on Monday relanuched its "wearable" for the treatment of migraines after undergoing a massive makeover, the company announced.

    Cefaly I, which gained popularity for its unique headband-like shape, is now three-quarters its size, fits in the palm of a person's hand, is rechargeable, uses magnets to stay in place and allows patients more control over the intensity of their daily session. The new Cefaly II, is available exclusively in the United States; it will become available next in Europe in September.

X
This ad will auto-close in 10 seconds